Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.
Nowakowski
Grzegorz S
GS
Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.
Witzig
Thomas E
TE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20